Notably, when Oxa(IV)@ZnPc@M (+) combined with anti-PD-L1, strongest antitumor effect among all groups on both primary and bone metastatic tumors were observed, with tumor shrinkage rate up to 99.4% and 95.1% respectively compared with PBS (+) group (Fig. 9b, c). The gene discussed is CD274; the disease is neoplasm.